PROPANC BIOPHARMA INC
PPCBNASDAQ🏆 #3895 by market capUS Equity
$527.74▼ $23.12 (−4.38%)
Simulated price1h—
24h▼ 4.4%
7d—
14d—
30d—
1y—
🏦Market Cap
$4M
Small Cap
📈Revenue Growth (YoY)
—
📊Gross Margin
—
💵FCF Margin
—
⚖️P/S Ratio
—
Otter Score
46
Weak
No chart data available for PPCB.
Trading Snapshot
- Day Range
- $525.85 – $534.77
- 52-Week Range
- $0.95 – $268.00
- Volume
- $1.90B
- Avg Volume
- $2.24B
- Shares Outstanding
- 2.3M
- Next Earnings
- Sep 11, 2026
Fundamentals Snapshot
- Annual Revenue
- $671,909
- Last Q Revenue
- $185,558
- P/E Ratio
- —
- P/S Ratio
- —
- EPS (TTM)
- $-25.66
- Dividend Yield
- —
Why Investors Own PPCB
- ✓High-growth profile — revenue up +2.3% YoY with expanding US Equity exposure.
- ✓Healthy economics — 75% gross margin and 13% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
Revenue (TTM)
$671,909▲ +2.9% YoY
Gross Margin (TTM)
74.9%▲ +3.4% YoY
Operating Income (TTM)
$75,254▲ +2.9% YoY
Free Cash Flow (TTM)
$86,004▲ +2.9% YoY
About PROPANC BIOPHARMA INC
A company profile for PROPANC BIOPHARMA INC isn’t available yet — check back soon.
🦦
Otter Score Breakdown
ⓘ💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
Overall Score
Weak
46/100
Analyst Price Target
ⓘAverage Target
$520.63
▼ −1.3% Downside
High Target$605.86
Low Target$441.42
Based on 38 analysts
Latest News & Updates
🚀
MarketWatch·2h ago
PROPANC BIOPHARMA INC tops quarterly estimates as demand accelerates
Revenue grew double digits with management guiding above consensus; margins continued to expand.
🛰️
MarketWatch·5h ago
Analysts lift PPCB price targets on improving margins
Several firms raised targets, citing stronger free cash flow and a healthier backlog.
🌌
MarketWatch·1d ago
PROPANC BIOPHARMA INC announces new agreement to expand its footprint
The move broadens the company’s reach and could add incremental revenue over the next year.